Similar articles for PMID: 32349970

Year	Number of Results
2004	2
2013	2
2014	4
2015	3
2016	11
2017	25
2018	20
2019	36
2020	23
2021	5

1

A practical approach to the cholesterol guidelines and ASCVD prevention.

Cho L. Cho L. Cleve Clin J Med. 2020 May;87(5 suppl 1):15-20. doi: 10.3949/ccjm.87.s1.02. Cleve Clin J Med. 2020. PMID: 32349970 Free article.

2

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.

Sabatine MS, Giugliano RP. Sabatine MS, et al. JAMA Cardiol. 2017 Sep 1;2(9):935-936. doi: 10.1001/jamacardio.2017.2293. JAMA Cardiol. 2017. PMID: 28768310 No abstract available.

3

The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.

Jia X, Al Rifai M, Birnbaum Y, Smith SC Jr, Virani SS. Jia X, et al. Curr Atheroscler Rep. 2019 Apr 2;21(6):20. doi: 10.1007/s11883-019-0784-8. Curr Atheroscler Rep. 2019. PMID: 30941517 Review.

4

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.

Leong D, Wu PE. Leong D, et al. CMAJ. 2019 Aug 12;191(32):E894. doi: 10.1503/cmaj.190107. CMAJ. 2019. PMID: 31405836 Free PMC article. No abstract available.

5

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Cannon CP, et al. JAMA Cardiol. 2017 Sep 1;2(9):959-966. doi: 10.1001/jamacardio.2017.2289. JAMA Cardiol. 2017. PMID: 28768335 Free PMC article.

6

Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.

Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J. Dixon DL, et al. Curr Atheroscler Rep. 2019 Mar 16;21(5):16. doi: 10.1007/s11883-019-0778-6. Curr Atheroscler Rep. 2019. PMID: 30877491 Review.

7

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA. Ray KK, et al. Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9. Cardiovasc Diabetol. 2019. PMID: 31706300 Free PMC article.

8

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?

Lloyd-Jones DM. Lloyd-Jones DM. JAMA Cardiol. 2017 Sep 1;2(9):937-938. doi: 10.1001/jamacardio.2017.2288. JAMA Cardiol. 2017. PMID: 28768306 No abstract available.

9

Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.

Wójcik C. Wójcik C. Postgrad Med. 2017 Nov;129(8):801-810. doi: 10.1080/00325481.2017.1376570. Epub 2017 Sep 14. Postgrad Med. 2017. PMID: 28879791 Review.

10

Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.

Miname MH, Bittencourt MS, Nasir K, Santos RD. Miname MH, et al. Curr Opin Lipidol. 2019 Apr;30(2):82-87. doi: 10.1097/MOL.0000000000000573. Curr Opin Lipidol. 2019. PMID: 30649025 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed